Euphorbia Factor L2 NEW
| Price | $68 | $158 | $228 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Euphorbia Factor L2 | CAS No.: 218916-51-9 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Euphorbia Factor L2 |
| Description | Euphorbia Factor L2 alleviates lipopolysaccharide-induced acute lung injury and inflammation through inhibits NF-κB activation. |
| In vivo | Euphorbia factor L2 (EFL2) on LPS-induced ALI in mice, where EFL2 attenuated pathological alterations in the lung and improved survival. Significant suppression of the recruitment and transmigration of inflammatory cells, specifically neutrophils, by 40?mg/kg of EFL2 was observed. EFL2 exerted potent anti-inflammatory effects by decreasing the levels of interleukin-1β (IL-1 β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF- α), interleukin-8 (IL-8) and myeloperoxidase (MPO) in the lung and bronchioalveolar lavage fluid. Consistent with the findings in vivo, EFL2 also showed robust inhibitory effects on the production of IL-1 β, IL-6, TNF- α and IL-8 released from LPS-stimulated RAW264.7 cells in vitro. Interestingly, this effect appeared to be mediated by EFL2's inhibition of NF-κB signaling activation, but not the MAPK pathway. Not only phosphorylation of IKK α/β and IκBα was down-regulated, p65 translocation and its DNA-binding activity were also significantly suppressed by EFL2. Moreover, overexpression of p65 reversed the inhibitory effect of EFL2 in LPS-induced NF-κB activation and cytokines production. The observed anti-inflammatory bioactivity of EFL2 indicates its potential as a drug development candidate, particularly for LPS-mediated disorders of inflammation[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 12 mg/mL (18.67 mM) |
| Keywords | Inhibitor | Euphorbia Factor L 2 | Apoptosis | Euphorbia Factor L-2 | inhibit | Euphorbia Factor L2 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Myricetin | Dextran sulfate sodium salt (MW 4500-5500) | Sodium 4-phenylbutyrate | L-Ascorbic acid | Metronidazole | Sorafenib | Tributyrin | Diallyl disulfide | Salicylic acid | Oleic acid |
| Related Compound Libraries | Terpene Natural Product Library | Bioactive Compound Library | Traditional Chinese Medicine Monomer Library | Anti-Inflammatory Traditional Chinese Medicine Compound Library | Natural Product Library for HTS | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $148.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/5mg |
Shanghai Standard Technology Co., Ltd.
|
2020-03-16 | ||
| $9.80/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-09 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY